ESPE2024 Rapid Free Communications GH and IGFs (6 abstracts)
Health-related quality of life at mid-puberty in adolescents with idiopathic isolated growth hormone deficiency
Joeri Vliegenthart 1 , Jan van Busschbach 2 , Jan Maarten Wit 3 , Boudewijn Bakker 4 , Annemieke Boot 5 , Christiaan de Bruin 3 , Martijn Finken 6 , Josine van der Heyden 7 , Anita Hokken-Koelega 8 , Hetty van der Kamp 9 , Sandra de Kort 10 , Edgar van Mil 11 , Ardine Reedijk 8 , Theo Sas 1 , Nina Schott 12 , Petra van Setten 13 , Saartje Straetemans 14 , Vera van Tellingen 15 , Bob Touwslager 16 , Paul van Trotsenburg 6 , Paul Voorhoeve 17 & Danielle van der Kaay 1
1Erasmus University Medical Centre, Sophia Children's Hospital, Rotterdam, Netherlands. 2Erasmus University Medical Centre, Rotterdam, Netherlands. 3Leiden University Medical Centre, Willem-Alexander Children's Hospital, Leiden, Netherlands. 4Reinier de Graaf Gasthuis, Delft, Netherlands. 5University Medical Centre Groningen, Beatrix Children's Hospital, Groningen, Netherlands. 6Amsterdam University Medical Center, Emma Children's Hospital, Amsterdam, Netherlands. 7Franciscus Gasthuis & Vlietland, Rotterdam, Netherlands. 8Dutch Growth Research Foundation, Rotterdam, Netherlands. 9University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, Netherlands. 10Juliana Children's Hospital, Haga Teaching Hospital, Den Haag, Netherlands. 11Jeroen Bosch Hospital, ‘s-Hertogenbosch, Netherlands. 12Zuyderland Hospital, Heerlen, Netherlands. 13Radboud University Medical Centre, Amalia Children’s Hospital, Nijmegen, Netherlands. 14Maastricht University Medical Center, MosaKids Children's Hospital, Maastricht, Netherlands. 15Catharina Hospital, Eindhoven, Netherlands. 16St. Antonius Hospital, Nieuwegein, Netherlands. 17Canisius Wilhelmina Hospital, Nijmegen, Netherlands
Introduction: Health related Quality of Life (QoL) outcome is used as an argument when continuation or stopping growth hormone (GH) treatment is considered in patients with idiopathic isolated growth hormone deficiency (IIGHD) who tested GH sufficient in mid-puberty (inclusion moment for this study).
Aim: To assess potential differences in QoL between patients with IIGHD who discontinued treatment and those who continued treatment.
Materials and Methods: Multicenter patient-preference study in patients at mid-puberty who were no longer GH deficient and chose to continue or stop GH treatment until near adult height (NAH). QoL was measured with a short stature specific questionnaire (QoLISSY) completed by patients and their parents. The questionnaire contained three core QoL domains (physical, emotional and social), three additional domains (coping, beliefs and treatment) and two specific domains for parents (future and effects on parents). Scores were transformed from raw scores to 0-100 scores. Higher values indicate better QoL.
Results: In total 127 patients participated: 44 continued GH treatment (GHcont) and 83 stopped treatment (GHstop). Height SDS (GHcont: -0.76±0.69 SDS vs GHstop: -0.47±0.85 SDS; P = 0.06) and age (GHcont: 14.0±1.1y vs GHstop: 13.9±1.1y; P = 0.69) were similar between groups. 74 patients (58%) completed the questionnaire; 22 in the GHcont (50%) and 52 in the GHstop (63%) group. Patient-reported total QoL scores were not significantly different (GHcont: 90.8±10SD vs GHstop: 92.7±11.1SD; P = 0.49), neither were the domain scores. Mean QoL was comparable with age- and sex-adjusted reference values. Parent-reported total QoL score was significantly higher in the GHstop than in the GHcont group (GHstop: 93.3±6.36SD vs GHcont: 85.1±14.7SD; P = 0.02), with significantly higher scores on the social, emotional and future domains.
Conclusion: Fifty-eight percent completed the questionnaires. Similar patient-reported QoL was observed between groups, while parents reported higher QoL when GH treatment was stopped at mid-puberty. These results establish a solid foundation for further exploration of QoL in this health care efficiency study.
Article tools
My recent searches
My recently viewed abstracts
Authors
ESPE Abstracts
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more